In vivo effects of human recombinant tumor necrosis factor alone and in combination with other biological response modifiers on human digestive organ cancer xenografts transplanted in nude mice

Yoshinori Nio, Takahiro Shiraishi, Michihiko Tsubono, Hideki Morimoto, Chen Chiu Tseng, Kazuya Kawabata, Yoshikazu Masai, Thein Tun, Manabu Fukumoto, Takayoshi Tobe

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

The present study was designed to evaluate the effect of rTNF alone or in combination with other BRMs on human digestive organ cancers. Six kinds of human digestive organ cancer xenografts (esophageal, stomach, colonic, pancreatic, bile duct, and liver cancers: EC-YO, GC-YN, CC-KK, PC-HN, BDC-SN and Li-7, respectively) were transplanted in nude mice, and rTNF was administered at 103, 5 × 103, or 104U/head directly into the tumor 3 times a week for 2 weeks. EC-YO was the most sensitive to rTNF, and intratumoral administration of rTNF at 103 U/head caused tumor regression. PC-HN, CC-KK and GC-YN were relatively sensitive to rTNF, and their growth was significantly inhibited by rTNF at 5 × 103 U/head, however, the tumors regrew after treatment. Li-7 and BDC-SN were resistant to rTNF. The effects of rTNF in combination with recombinant interferon-γ (rIFN-γ), recombinant interleukin-2 (rIL-2), or streptococcal preparation OK-432 were assessed in mice transplanted with GC-YN. All combinations of rTNF at 5 × 103 U/head and other BRMs were more effective than rTNF alone, and GC-YN tumors were completely regressed after treatment with a combination of rTNF and rIFN-γ or rTNF and OK-432. However in all cases, the combination of rTNF at 103 U/head and any other BRM did not improve the effect. Furthermore, the adverse effects of the combinations were more serious than those of rTNF alone. TNF may still be a useful cytokine, because it can induce the regression of tumors. However, for its clinical application, a method should be developed to reduce its side effects.

Original languageEnglish
Pages (from-to)337-344
Number of pages8
JournalBiotherapy
Volume3
Issue number4
DOIs
Publication statusPublished - 1991 Oct 1

Keywords

  • Picibanil (OK-432)
  • human tumor xenograft
  • interferon (IFN)
  • interleukin-2 (IL-2)
  • nude mouse
  • tumor necrosis factor (TNF)

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'In vivo effects of human recombinant tumor necrosis factor alone and in combination with other biological response modifiers on human digestive organ cancer xenografts transplanted in nude mice'. Together they form a unique fingerprint.

Cite this